![]() |
Volumn 344, Issue 11, 2001, Pages 824-831
|
The cost effectiveness of combination antiretroviral therapy for HIV disease
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
INDINAVIR;
LAMIVUDINE;
VIRUS RNA;
ZIDOVUDINE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ARTICLE;
COST EFFECTIVENESS ANALYSIS;
DISEASE COURSE;
HEALTH CARE COST;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LIFE EXPECTANCY;
LYMPHOCYTE COUNT;
MATHEMATICAL MODEL;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
SIMULATION;
UNITED STATES;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
ANTI-HIV AGENTS;
CD4 LYMPHOCYTE COUNT;
COMPUTER SIMULATION;
COST-BENEFIT ANALYSIS;
DIRECT SERVICE COSTS;
DISEASE PROGRESSION;
DRUG COSTS;
DRUG THERAPY, COMBINATION;
HEALTH CARE COSTS;
HIV INFECTIONS;
HUMANS;
LIFE EXPECTANCY;
MODELS, BIOLOGICAL;
QUALITY-ADJUSTED LIFE YEARS;
RNA, VIRAL;
UNITED STATES;
VALUE OF LIFE;
|
EID: 0035869435
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJM200103153441108 Document Type: Article |
Times cited : (457)
|
References (46)
|